Search > Solid Tumors
My employer runs this trial

Adagrasib + Other Treatments for Solid Tumors

Not yet recruiting at 29 trial locations
BC
Overseen ByBMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Mirati Therapeutics Inc.
Must be taking: Adagrasib
Disqualifiers: Completed treatment, Progressed, Discontinued due to toxicity
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

What You Need to Know Before You Apply

What is the purpose of this trial?

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.

Who Is on the Research Team?

BS

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Are You a Good Fit for This Trial?

Inclusion Criteria

* Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.
I was assigned female at birth and cannot become pregnant, or I use birth control as required.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive adagrasib as monotherapy or in combination with other cancer therapies

Long-term

Follow-up

Participants are monitored for safety and effectiveness after treatment

4-8 weeks

Open-label extension

Participants continue to receive adagrasib treatment as part of the rollover trial

Indefinite

What Are the Treatments Tested in This Trial?

Interventions

  • Adagrasib

How Is the Trial Designed?

10

Treatment groups

Experimental Treatment

Group I: Arm C4Experimental Treatment3 Interventions
Group II: Arm C3Experimental Treatment3 Interventions
Group III: Arm C2Experimental Treatment1 Intervention
Group IV: Arm C1Experimental Treatment1 Intervention
Group V: Arm B4Experimental Treatment3 Interventions
Group VI: Arm B3Experimental Treatment2 Interventions
Group VII: Arm B2Experimental Treatment2 Interventions
Group VIII: Arm B1Experimental Treatment2 Interventions
Group IX: Arm A2Experimental Treatment1 Intervention
Group X: Arm A1Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mirati Therapeutics Inc.

Lead Sponsor

Trials
73
Recruited
8,900+

Dr. Charles M. Baum

Mirati Therapeutics Inc.

Chief Executive Officer since 2023

MD, PhD

Dr. Joseph Leveque

Mirati Therapeutics Inc.

Chief Medical Officer since 2021

MD

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.